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The fibroblast growth factors (FGFs) exert their diverse (or pleiotropic) biological responses through the
binding and activation of specific cell surface receptors (FGFRs). While FGFRs are known to initiate intra-
cellular signaling through receptor tyrosine phosphorylation, the precise mechanisms by which the FGFRs
regulate pleiotropic biological responses remain unclear. We now identify a new mechanism by which FGFR2
is able to regulate intracellular signaling and cellular responses. We show that FGFR2 is phosphorylated on
serine 779 (S779) in response to FGF2. S779, which lies adjacent to the phospholipase C binding site at Y766,
provides a docking site for the 14-3-3 phosphoserine-binding proteins and is essential for the full activation of
the phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase pathways. Furthermore, S779
signaling is essential for promoting cell survival and proliferation in both Ba/F3 cells and BALB/c 3T3
fibroblasts. This new mode of FGFR2 phosphoserine signaling via the 14-3-3 proteins may provide an increased
repertoire of signaling outputs to allow the regulation of pleiotropic biological responses. In this regard, we
have identified conserved putative phosphotyrosine/phosphoserine motifs in the cytoplasmic domains of di-
verse cell surface receptors, suggesting that they may perform important functional roles beyond the FGFRs.
The fibroblast growth factors (FGFs) constitute a large fam-
ily of proteins (22 members) that mediate diverse (or pleiotro-
pic) cellular responses such as cell survival, proliferation, dif-
ferentiation, and migration (7, 9). The pleiotropic activities
mediated by FGFs are essential for the regulation of such
dynamic processes as embryogenesis, wound healing, tissue
repair, and angiogenesis (9). The FGFs exert their biological
activities through the binding and activation of four structur-
ally related FGF receptors (FGFR): FGFR1 (Flg), FGFR2
(Bek), FGFR3, and FGFR4, each of which is subject to alter-
native mRNA splicing to generate receptors with distinct li-
gand-binding specificities (37). The prototypic members of the
FGF family of growth factors, FGF1 (acidic FGF) and FGF2
(basic FGF), are able to bind FGFR1 and FGFR2, leading to
receptor dimerization/oligomerization, activation of intrinsic
receptor tyrosine kinase activity, and the phosphorylation of
specific tyrosine residues in the cytoplasmic tail of the receptor
(9). As widely observed for other receptor tyrosine kinases
(RTKs), phosphotyrosine residues in the cytoplasmic domains
of FGFR1 and FGFR2 provide docking sites for Src-homology
2 (SH2) domain proteins and allow the activated receptor to
physically couple to downstream signaling pathways (45,
54, 58).
In the case of FGFR1, seven tyrosine residues in the cyto-
plasmic domain have been identified as phosphorylation sites:
Y463 in the juxtamembrane domain (13, 29, 34), Y583 and
Y585 in the kinase insert domain (13, 21, 34), Y653 and Y654
in the activation loop of the kinase domain (13, 21, 34), and
Y730 (34) and Y766 (29, 35) in the C-terminal lobe. Of these
seven tyrosine residues, Y653 and Y654 are essential for allo-
steric regulation of kinase activity (34), while the remaining
five are either known or putative docking sites for SH2 domain
proteins. Given that all seven phosphorylation sites identified
in FGFR1 are conserved in FGFR2, a similar tyrosine phos-
phorylation profile would be expected for FGFR2.
Despite the identification of multiple FGFR tyrosine phos-
phorylation sites, it has proved difficult to functionally link
individual FGFR1 or FGFR2 tyrosine residues to specific cel-
lular responses. For example, Y766 has been shown to act as a
binding site for phospholipase C (PLC-) (36), and mutation
of this site results in a receptor that is defective in PLC-
activation and phosphatidylinositol (PI) (4, 5) biphosphate hy-
drolysis (35, 49). In addition, Y766 has also been shown to bind
the adaptor proteins Shb (6) and Grb14 (51). However, the
precise functional role of Y766 in mediating specific cellular
responses remains unclear. Despite being essential for PI hy-
drolysis and calcium flux, Y766 of FGFR1 was not required for
the proliferation of L6 myoblasts, Ba/F3 cells, or porcine aortic
endothelial cells (5, 22, 35, 49); the neuronal differentiation of
PC12 cells (60); or mesoderm induction in Xenopus (38). Al-
though none of these studies identified an essential role for
Y766 in mediating specific biological responses, a more recent
study suggested that Y766 might play a negative role in FGFR1
signaling. A genetic knock-in of a Y766F mutant of FGFR1 in
mice appeared to result in a gain-of-function receptor that led
to a partially penetrant phenotype in vertebrate column for-
mation (44). Apart from Y766, a role for the membrane-prox-
imal Y463 in the recruitment of the Crk adaptor protein and
the proliferation of porcine aortic endothelial cells has also
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been reported (25). However, other studies utilizing ap-
proaches that included domain swapping of the cytoplasmic
regions of the FGFRs as well as specific receptor tyrosine
mutants suggested that that neither Y463 nor Y766 was nec-
essary for PC12 differentiation (12).
While the FGFRs are able to directly couple to SH2 domain
proteins via specific phosphotyrosine docking sites in their
cytoplasmic tails, the FGFR substrate 2 (FRS2) proteins also
associate with the FGFRs and act as scaffolds for the recruit-
ment of signaling proteins (23). The FRS2 proteins associate
with the membrane-proximal region of the FGFRs in a phos-
photyrosine-independent manner and then recruit specific
SH2 domain proteins such as Grb2, Gab1, and Shp2 (20, 41).
Thus, the ability of the FGFRs to recruit signaling proteins
through phosphotyrosine residues in their cytoplasmic tails as
well as via the FRS2 proteins may impart specific signaling
capabilities to regulate a unique spectrum of pleiotropic activ-
ities (55).
However, in addition to receptor tyrosine phosphorylation
and the recruitment of SH2 and phosphotyrosine binding
(PTB) domain proteins, it has recently become apparent that
growth factor and cytokine receptors also initiate intracellular
signaling via receptor serine/threonine phosphorylation and
the recruitment of phosphoserine/threonine binding proteins.
While serine/threonine phosphorylation has long been re-
garded as solely an allosteric regulator of protein activity, the
recent discovery of a number of phosphoserine/threonine-
binding proteins or modules has radically altered this view (14,
30, 71). For example, the 14-3-3 family of proteins are able to
bind phosphoserine/threonine residues within a sequence-spe-
cific context (1, 30, 71). Because the 14-3-3 proteins are able to
form stable dimers in which each subunit is able to bind a
separate phosphoserine peptide, it has been suggested that
these proteins may function as adaptors or scaffolds for the
assembly of signaling complexes (30). For example, our previ-
ous studies have shown that S585 phosphorylation of the c
subunit in the granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) and interleukin-3 (IL-3) receptors results in
binding of the 14-3-3 proteins, the recruitment of PI 3-kinase,
and the regulation of hemopoietic cell survival (17–19, 62).
While the 14-3-3 proteins have been shown to bind phospho-
serine residues in the cytoplasmic tails of a number of other
growth factor and cytokine receptors such as the IL-9 receptor
 (57), insulin-like growth factor 1 receptor (IGF-1R) (4), the
epidermal growth factor (EGF) receptor (39), the prolactin
receptor (40), and the transforming growth factor  receptor
(33), the biological significance of these 14-3-3–receptor inter-
actions is unclear. In addition to 14-3-3, a number of other
phosphoserine/threonine binding domains have been identi-
fied including the tryptophan-tryptophan domain (28), the
MH2 domains of R-Smads, and the Forkhead-associated,
BRCA1 C-terminal, and polo-box domains (14, 30, 69–71).
Thus, growth factor receptors may utilize two distinct strate-
gies for the phosphorylation-dependent recruitment of adaptor
or scaffold proteins to their cytoplasmic tails: one through
receptor tyrosine phosphorylation and the recruitment of SH2
or PTB domain proteins and the other through receptor serine/
threonine phosphorylation and the recruitment of phospho-
serine/threonine binding proteins such as 14-3-3.
To directly examine this possibility, we scanned the cytoplas-
mic tails of cell surface receptors for possible 14-3-3 binding
sites. We noted that FGFR2 contained a conserved putative
14-3-3 binding site at S779, which lies nearby Y766 in the
C-terminal lobe. We developed phospho-specific anti-phos-
pho-S779 antibodies and showed that FGF2 stimulation of
Ba/F3 cells expressing FGFR2 results in the phosphorylation
of S779. Furthermore, we showed that phospho-S779 was able
to bind the 14-3-3 proteins in response to FGF2 stimulation.
Expression of an S779G mutant unable to bind the 14-3-3
proteins in either Ba/F3 cells or BALB/c fibroblasts impaired
intracellular signaling via the PI 3-kinase and Ras/mitogen-
activated protein (MAP) kinase pathways in response to
FGF2. Significantly, the S779G mutant was unable to promote
cell proliferation of either Ba/F3 cells or BALB/c fibroblasts
following FGF2 stimulation. Together, these results identify a
new phosphoserine-dependent mechanism by which the FGFRs
initiate intracellular signaling pathways leading to specific bi-
ological outcomes and further suggest that such novel modes
of signaling may serve essential roles downstream of diverse
growth factor and cytokine receptors.
MATERIALS AND METHODS
FGFR2 constructs. Y766 and S779 of FGFR2 cDNA (denoted here as BEK)
were mutagenized in pBluescript (pB-KS). pB-BEK-HindII/RI was generated by
subcloning a HindII/EcoRI fragment from pGC37 into pB. In addition, a 119-bp
EcoR1/BglII fragment containing the 3 coding region of FGFR2 was subcloned
into the EcoRI/blunted-BglII site in pB to give pB-BEK-RI/BglII. Tyr766 and
Ser779 were mutagenized in pB-BEK-RI/BglII using standard QuickChange
mutagenesis. Mutagenic primers were 5-CTCACAACCAATGAAGAATTTC
TGGACCTCAGCCAACC-3 (Tyr766Phe mutation) and 5-GAACAGTATTC
ACCCGGGTACCCTGACACAAGAAG-3 (Ser779Gly mutation). An XhoI/
EcoRI fragment from pB-BEK-HindIII/RI was then subcloned into pB-BEK-
RI/BglII-mutagenized plasmids to give pB-BEK-wt (where wt is wild type),
pB-BEK-YF (where YF is yellow fluorescent protein), pB-BEK-SG, and pB-
BEK-YF/SG containing full-length BEK cDNA. HindIII/XbaI fragments were
then subcloned into the RcCMV (where CMV is cytomegalovirus) plasmid to
give RcCMV-BEK-wt, RcCMV-BEK-YF, RcCMV-BEK-SG, and RcCMV-
BEK-YF/SG. The complete open reading frames of all plasmids were sequenced
to confirm specific mutations.
Antibody production. The anti-phospho-S779 phospho-specific antibody was
generated using phospho-peptide encompassing Ser779 of FGFR2 (KEQYSPp
SYPDTRC, where pS is phosphoserine) (Chemicon). Reverse-phase high-per-
formance liquid chromatography-purified peptides were subjected to mass spec-
trometry analysis to confirm correct molecular weights. The phospho-S779
peptide was coupled to keyhole limpet hemocyanin and injected into New Zea-
land White rabbits. Immunoreactivity was examined from test bleeds using non-
phospho-Ser779 and phospho-Ser779 peptides in a dot blot format.
Cell lines. Ba/F3 cells stably expressing RcCMV-wt-FGFR2, FGFR2 carrying
the mutation Y766F (FGFR2-Y766F), FGFR2-S779G, and FGFR2-Y766F/
S779G were generated by electroporation with individual constructs while
BALB/c 3T3 stable transfectants were generated by CaPO4. Transfection was
followed by selection in G418 for 2 weeks (Invitrogen). For BALB/c 3T3 cells,
individual clones were isolated and examined for their ability to proliferate in
response to FGF2 using a Cell Titer 96 colorimetric assay (Promega). Ba/F3 cells
were maintained in RPMI medium supplemented with 10% fetal calf serum
(FCS) and 10% WEHI 3B medium. BALB/c 3T3 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FCS.
FACS analysis of FGFR2 expression. Cells were pelleted, washed in phos-
phate-buffered saline (PBS), and resuspended in PBS–0.1% FCS with or without
1 g of FGFR2 H1 antibody and incubated on ice for 60 min. Cells were washed
in PBS three times and incubated with anti-rabbit-fluorescein isothiocyanate
(FITC) in PBS–0.1% FCS for 60 min, washed, and analyzed by fluorescence-
activated cell sorting (FACS).
Viability assays. Cells were seeded in 96-well plates in the presence or absence of
20 ng/ml FGF2 (R&D Systems). Ba/F3 cells were seeded at 5  104 cells per well in
RPMI medium containing 0.1% FCS while BALB/c 3T3 cells were plated at 1,000
cells/well in DMEM containing either 10% BIT (stem cell Technologies) or 10%
FCS. Viability was assayed following a 24-h culture for Ba/F3 cells and after a 3-day
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culture for BALB/c 3T3 cells by staining with MTS [3,4-(5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt] reagent and mea-
suring absorbance at the optical density at 490 nm.
Apoptosis assay. Stably transfected Ba/F3 cells were seeded at 6.7  104
cells/well (24-well tray) into RPMI medium containing 0.1% FCS in the presence
or absence of 0.5 or 5 ng/ml FGF2. Cells were cultured for 24 h and then pulsed
with 200 nM TMRE (tetramethylrhodamine ethyl ester; Invitrogen) for 30 min,
washed in PBS, and analyzed by flow cytometry on the FL2 channel. Results are
representative of at least three experiments. Error bars indicate standard devi-
ations.
Proliferation assay. Stably transfected Ba/F3 cells were seeded at 2.3  104
cells/well (24-well plates) into RPMI medium containing 0.1% FCS in the pres-
ence or absence FGF2. Cells were cultured for 24 h and then pulsed with 10 M
bromodeoxyuridine (BrdU; Roche) for 3 h, washed, fixed (3 volumes of 50 mM
glycine [pH 2] and 7 volumes of absolute ethanol) for 30 min at 4°C, washed in
PBS, resuspended in 4 M HCl, and incubated at room temperature for 20 min.
Cells were then washed twice, resuspended in block solution (1:20 dilution of
blocking agent [Roche] in PBS) and a 1:10 dilution of anti-BrdU-FITC antibody
(Roche), and incubated at 37°C in 5% CO2 for 45 min. Following staining cells
were washed and analyzed by flow cytometry. Results are representative of at
least three experiments. Error bars indicate standard deviations.
Analysis of sub-G1 and cell cycle progression. Cells were fixed in 70% ethanol
for 1 h at 4°C, washed, resuspended at a 1:1 ratio of PBS and DNA extraction
buffer (0.2 M Na2HPO4, 0.1 M citric acid, pH 7.8), and incubated for 5 min;
samples were then centrifuged, resuspended in propidium iodide staining solu-
tion (3.8 mM sodium citrate, 50 mg/ml propidium iodide in PBS) with 500 g of
RNase A, and incubated for 30 min. Cells were analyzed by FACS.
Immunoprecipitation, pull-down assays, and Western blotting. Ba/F3 cells (2 
107 cells/immunoprecipitation) stably expressing wt FGFR2, FGFR2-Y766F,
FGFR2-S779G, or FGFR2-Y766F/S779G were factor and serum starved in
RPMI medium containing 0.1% FCS for 4 h prior to stimulation with 20 ng/ml
FGF2 for the various times. For inhibitor treatments cells were preincubated
with inhibitor for 30 min prior to stimulation with FGF. LY294002 (Calbiochem)
was used at 33 M. Wortmannin (Santa Cruz) was used at 100 nM. Rapamycin
(Sigma) was used at 1 M. Glycogen synthase kinase 3 (GSK3) VIII (Calbio-
chem) was used at 1 M. BAY11-7082 (Sigma) was used at 100 M. H89
(Calbiochem) was used at 0.5 M. SU5402 (Calbiochem) was used at 100 M.
Stably transfected BALB/c 3T3 clones were starved overnight in DMEM con-
taining 0.5% FCS, following which cells were stimulated with 20 ng/ml FGF2 for
10 min. Cells were lysed in NP-40 buffer (10 mM Tris [pH 7.4], 137 mM NaCl,
10% glycerol, 1% Nonidet P-40) supplemented with 10 mM -glycerolphos-
phate, 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, 10 mM Na orthovana-
date, and 4.5 U/ml aprotinin (Sigma). Cleared lysates were subjected to immu-
noprecipitation for 2 h at 4°C on a rotating wheel with 1 g of anti-FGFR2 C17
antibody (Santa Cruz) or CN-14-3-3 adsorbed to protein A-Sepharose. Immu-
noprecipitates and pull-downs were washed in NP-40 buffer resolved via sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Immunopre-
cipitates were immunoblotted with 4G10, anti-phospho-S779 FGFR2, anti-
FGFR2 C17 (Santa Cruz), and EB1 while pull-downs were immunoblotted with
anti-FGFR2 C17. Cleared cell lysates were also subjected to SDS-PAGE and
immunoblotted with anti-phospho-Akt (Cell Signaling Technology), anti-phos-
pho-extracellular signal-regulated kinase 1 and 2 (ERK1/2), anti-phospho-PLC-
(Biosource), anti-phospho-GSK3/ (Cell Signaling Technology), anti-actin
(Chemicon), or anti-ERK1/2 (Promega) antibodies.
PI-3 kinase reporter assay. Ba/F3 cells stably expressing wt FGFR2, FGFR2-
Y766F, FGFR2-S779G, or FGFR2-Y766F/S779G were electroporated with 20
g of yellow fluorescent protein-pleckstrin homology (PH) domain of Akt1.
After 24 h cells were factor and serum deprived for 8 h in RPMI medium
containing 0.1% FCS prior to stimulation with 20 ng/ml FGF2 or IL-3 for various
times. Cells were fixed (3.7% formaldehyde in PBS) and analyzed under a
fluorescent confocal microscope.
Immunofluorescence. Ba/F3 cells stably expressing wt FGFR2 or FGFR2-
S779G were factor and serum deprived for 4 h in RPMI medium containing 0.1%
FCS prior to stimulation with 20 ng/ml FGF2 for the indicated times in the
presence of heparin. Cells were then adhered onto poly-L-lysine-coated cover-
slips and fixed (3.7% formaldehyde in PBS). Cells were washed three times each
with PBS and PBS-Tween, permeabilized with 0.1% Triton X-100, and incubated
with blocking solution (1% bovine serum albumin) for 1 h at room temperature.
Slides were probed with anti-FGFR2 antibody overnight at 4°C, washed in
PBS-Tween, incubated with anti-rabbit antibody-Alexa488 (Invitrogen) and
phalloidin-Alexa555 (Invitrogen) for 2 h at room temperature, washed, and
analyzed by fluorescent confocal microscopy.
Cross-linking. Ba/F3 cells stably expressing wt FGFR2 or FGFR2-S779G were
incubated with 20 ng/ml FGF at 4°C for 4 h. Cells were then left untreated or
treated with BS3 cross-linker (Pierce) for 30 min, washed with PBS, and lysed.
Cleared cell lysates were then subjected to SDS-PAGE and immunoblotted with
anti-FGFR2 C17 antibody (Santa Cruz).
Protein stability assays. Ba/F3 cells stably expressing wt FGFR2 or FGFR2-
S779G were seeded in RPMI medium supplemented with 10% FCS–10% WEHI
3B medium and 10 g/ml cycloheximide (Sigma) in the presence or absence of
20 ng/ml FGF for up to 24 h. Following incubation, cells were lysed, and cleared
lysates were subjected to SDS-PAGE and immunoblotted with anti-FGFR2 C17
antibody (Santa Cruz).
Predikin analysis. Predikin 2.0 analysis was performed essentially as described
by Brinkworth et al. (3) using a Web-based interface (http://predikin.biosci.uq
.edu.au/pkr/). Predikin analysis entailed analysis using both the kinase substrate
database (KSD) and the substrate-determining residues (SDRs). SDRs are con-
served amino acids, located in the catalytic domain of a serine/threonine kinase,
which determine whether a protein is a likely substrate for the kinase. A database
search identifies protein kinases with similar SDRs and, where possible, the
phosphorylation sites at which they act. The phosphorylation sites are used to
build a frequency matrix describing the predicted amino acid frequency at po-
sitions 3 to 3 for query kinases. The frequencies are converted to weights,
which can be used to scan and score an input substrate sequence. For KSD
analysis, a database query selects kinases of the same KSD family and their
phosphorylation sites. The sites are used to build frequency and weight matrices
that can be used to screen and score a substrate sequence.
RESULTS
S779 of FGFR2 is phosphorylated in response to FGF2
and binds the 14-3-3 proteins. A schematic representation of
FGFR2 is shown in Fig. 1A. The cytoplasmic domain of
FGFR2 contains seven known phosphorylation sites (Y463,
Y583, Y585, Y653, Y654, Y730, and Y766), each of which is
conserved across mammalian species in both FGFR2 and
FGFR1. While some of these tyrosines have been linked to the
regulation of specific signaling events, it has proved more dif-
ficult to functionally link individual tyrosine residues to specific
biological responses (5, 22, 24, 35, 49, 60). We therefore con-
sidered the possibility that other nontyrosine motifs in the
cytoplasmic domain of the FGFR may be important for regu-
lating specific biological responses. We along with others have
previously shown that the 14-3-3 family of proteins are able to
bind specific phosphoserine residues in the cytoplasmic do-
mains of cytokine and growth factor receptors (4, 17–19, 32, 39,
40, 52, 57, 62). The prototypic consensus binding motifs for the
14-3-3 proteins are R-S-X-S/T-X-P (mode 1) and R-X-	-X-S/
T-X-P (mode 2) (where S/T is a phosphoserine/threonine, X is
any amino acid, and 	 is a hydrophobic residue) (71). More
recently, we along with others have identified 14-3-3 binding
sites that do not strictly conform to these prototypic motifs (2,
62, 68). We identified one possible 14-3-3 binding site at S779
in FGFR2 (775Q-Y-S-P-S-Y-P781, where S represents the pu-
tative phospho-S779) (Fig. 1A). Importantly, S779 lies distal to
Y766 in the C-terminal lobe (Fig. 1A) and is conserved across
mammalian species in both FGFR2 and FGFR1.
To determine whether the 14-3-3 proteins were able to di-
rectly interact with phospho-S779, we examined the ability of
peptides encompassing the putative 14-3-3 binding site in
FGFR2 to pull down purified recombinant 14-3-3
 in vitro. As
shown in Fig. 1B, the phospho-S779 peptide was able to pre-
cipitate recombinant 14-3-3
 while the non-phospho-S779 pep-
tide did not. Furthermore, the phospho-S779 peptide was able
to precipitate 14-3-3 from Ba/F3 whole-cell lysates (Fig. 1B).
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These results indicate that S779 of FGFR2 lies within a 14-3-3
binding site and could potentially bind the 14-3-3 proteins.
To test the possibility that S779 could bind the 14-3-3 pro-
teins within the context of the full-length receptor in cells, we
generated a construct for the expression of FGFR2-S779G. In
addition, we also generated constructs in which the PLC-
binding site at Y766 was mutated (FGFR2-Y766F) or both the
PLC- and 14-3-3 binding sites were mutated (FGFR2-Y766F/
S779G). We utilized the Ba/F3 cell system that has been widely
used to examine FGFR signaling and functions (22, 26, 42, 59,
66). Importantly, Ba/F3 cells do not express endogenous FGFRs
and therefore allow intracellular signaling and biological re-
sponses mediated by wt and mutant FGFRs to be character-
ized in an FGFR-null background. Pools of Ba/F3 cells stably
expressing either wt or mutant FGFR2 were isolated. Analysis
of surface receptor expression by flow cytometry indicated that
wt and mutant FGFR2s were expressed at equivalent levels
(Fig. 1C). We first examined the ability of 14-3-3 to interact
with wt and mutant FGFR2s in a pull-down experiment using
either Sepharose resin (control) or 14-3-3
–Sepharose. As
shown in Fig. 2A, 14-3-3
–Sepharose was able to precipitate
the wt FGFR2 while essentially no interaction with the Sepha-
rose control was detected. However, while 14-3-3
–Sepharose
was able to precipitate the Y766F mutant, interaction with the
FGFR2-S779G and the FGFR2-Y766F/S779G mutants was
reduced by more than sevenfold (Fig. 2A).
Although, the ability of 14-3-3
 to precipitate FGFR2 did
not appear to be regulated by FGF2 stimulation in the exper-
iments shown in Fig. 2A, these experiments did not address
whether endogenous 14-3-3 was able to associate with S779 of
FGFR2 in response to ligand. We therefore examined the
ability of FGFR2 to coimmunoprecipitate with 14-3-3 in re-
sponse to FGF2. As shown in Fig. 2B, wt and FGFR2-Y766F
coimmunoprecipitated with endogenous 14-3-3 in response to
FGF2 stimulation, whereas no such interaction was detectable
for the FGFR2-S779G and FGFR2-Y776F/S779G mutants.
We therefore sought to determine whether S779 of FGFR2
was phosphorylated in response to FGF2. For these experi-
ments, we generated anti-phospho-S779 phospho-specific poly-
clonal antibodies (described in Materials and Methods). These
antibodies were shown to specifically recognize a phospho-
S779 peptide but not a non-phospho-S779 peptide in dot blot
experiments (Fig. 2C). As an additional control, we further
showed that the anti-phospho-S779 phospho-specific poly-
clonal antibodies did not recognize a phosphoserine peptide
derived from a different 14-3-3 binding site in the GM-CSF
receptor (Fig. 2C). As shown in Fig. 2D, FGF2 stimulation of
Ba/F3 cells expressing wt FGFR2 resulted in a rapid increase
in S779 phosphorylation. Importantly, no phosphorylation was
observed for the FGFR2-S779G mutant, further demonstrat-
ing the specificity of the anti-phospho-S779 antibodies.
We further examined whether mutation of S779 had an
impact on FGFR2 tyrosine phosphorylation. As shown in Fig.
3A, equivalent levels of receptor tyrosine phosphorylation
were observed in Ba/F3 cells expressing either wt FGFR2,
FGFR2-Y766F, FGFR2-S779G, or FGFR2-Y766F/S779G fol-
lowing FGF2 stimulation. To further confirm that there was no
overall defect on receptor tyrosine phosphorylation for each of
the mutants, we also generated BALB/c 3T3 cell lines stably
expressing wt FGFR2, FGFR2-S779G, FGFR2-Y766F, and
FGFR2-Y766F/S779G. As shown in Fig. 3B, no detectable
difference was observed between the wt and mutant FGFR2s
in terms of receptor tyrosine phosphorylation. We then com-
pared the kinetics of S779 phosphorylation with FGFR2 ty-
rosine phosphorylation. As shown in Fig. 3C, the induction of
FIG. 1. Schematic representation of FGFR2 and the identification
of a putative 14-3-3 binding site at S779. (A) Shown are immunoglob-
ulin-like (Ig) domains (D1, D2, and D3), the acidic box (A), the
transmembrane domain (TM), the juxtamembrane domain, the split
tyrosine kinase domain, and the C-terminal lobe. Conserved cytoplas-
mic tyrosine autophosphorylation sites are indicated, and the putative
14-3-3 binding site surrounding S779 is underlined. (B) The ability of
either non-phospho-S799 (S779) or phospho-S799 (P-S779) peptides
encompassing S779 of FGFR2 to precipitate recombinant purified
14-3-3
 and 14-3-3 from Ba/F3 lysates was examined using a pull-down
approach. Pull-downs were subjected to SDS-PAGE and immunoblot
analysis using anti-14-3-3 polyclonal antibody. Results are representa-
tive of at least two experiments. (C) Pools of transfected Ba/F3 cells
stably expressing either wt FGFR2, FGFR2-Y766F, FGFR2-S779G, or
FGFR2-Y766F/S779G were first stained with either a control (shaded
profile) or FGFR2 primary antibodies (open profile), followed by
FITC-conjugated anti-rabbit secondary antibodies, and cell surface
expression of FGFR2 was analyzed by flow cytometry.
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both S779 phosphorylation and tyrosine phosphorylation of
FGFR2 both occurred within 5 min; however, while receptor
tyrosine phosphorylation was clearly transient, S779 phosphor-
ylation was sustained and persisted for up to 4 h. It is also
important to note that lack of S779 phosphorylation and 14-3-3
binding in the S779G mutant did not affect receptor tyrosine
phosphorylation induction or kinetics (Fig. 3C).
Induction of S779 phosphorylation by the protein kinase C
(PKC) family of kinases. As an initial step toward the identi-
fication of kinases involved in S779 phosphorylation, we per-
formed Predikin analysis, which is a predictive algorithm that
can be used to identify substrates for known kinases (3).
Predikin utilizes data from available crystal structures, molec-
ular modeling, and the sequence analysis of kinases and sub-
strates to predict the requirements for binding of a heptapep-
tide substrate motif to a specific kinase. In silico analysis using
Predikin, version 2.0 (http://predikin.biosci.uq.edu.au/pkr/),
that incorporated both the SDRs and the KSD resulted in the
identification of a number of kinases with scores of 65 (out of
100), indicating a potential to phosphorylate S779. These ki-
nases included PKC (score, 76.89), IB kinase (IKK; score,
67.42), Akt (also known as PKB; score, 72.87), and GSK3
(score, 84.23). We then examined the possible involvement of
these candidate kinases identified by Predikin by examining the
pharmacological profile of S779 phosphorylation using inhibi-
tors for PI 3-kinase (LY294002 and Wortmannin), mTOR
(rapamycin), GSK3 (VIII), IKK (BAY11-7082), PKA (H89),
JAK tyrosine kinases (JAKI), and the FGFR2-specific tyrosine
kinase inhibitor SU5402. While Predikin reported PKC as a
potential S779 kinase, Davies et al. have shown very clearly
that essentially all widely used PKC inhibitors have very poor
selectivity (8). We therefore examined the ability of a widely
used specific activator of PKC, phorbol 12-myristate 13-acetate
(PMA), to induce ligand-independent S779 phosphorylation.
As shown in Fig. 3D, neither H89, Wortmannin, rapamycin,
LY294002, JAKI, GSK31, or BAY11-7082 was able to block
(or reduce) S779 phosphorylation in response to FGF2. Thus,
our data exclude a role for these kinases (or their downstream
targets) in phosphorylating S779. However, we observed an
increase in S779 phosphorylation following PMA stimulation,
suggesting the involvement of the PKC family of kinases. Time
course experiments showed that the induction of S779 phos-
phorylation by PMA demonstrated similar kinetics to those
observed following FGF2 stimulation (data not shown). These
FIG. 2. S779 of FGFR2 is phosphorylated in response to FGF2 and binds the 14-3-3 family of proteins. Ba/F3 cells expressing either wt FGFR2,
FGFR2-Y766F, FGFR2-S779G, or FGFR2-Y766F/S779G were starved in medium containing 0.1% FCS for 4 h and then stimulated with 20 ng/ml
FGF2 for the indicated times. (A) Cells were then lysed and pull-downs performed using either Sepharose alone (control) or CnBr-coupled
14-3-3
–Sepharose. Pull-downs were resolved by SDS-PAGE and immunoblotted with anti-FGFR2 polyclonal antibody. (B) In addition, cells were
also stimulated as above, and 14-3-3 was immunoprecipitated. Immunoprecipitates were subjected to SDS-PAGE and immunoblotted with
anti-FGFR2 polyclonal antibody. (C) Specificity of anti-phospho-S779 phospho-specific antibodies was confirmed in dot blot assays. A total of 4
g of non-phospho-S799 (S779) or phospho-S799 (P-S779) peptide encompassing the 14-3-3 binding site at S779 of FGFR2 (left panel) or
non-phospho-S585 (S585) or phospho-S585 (P-S585) control peptide encompassing a different 14-3-3 binding site in the GM-CSF receptor
(GM-CSFR) was blotted onto nitrocellulose and incubated with anti-phospho-S779 antibody followed by anti-rabbit horseradish peroxidase-
conjugated secondary antibody. (D) Ba/F3 cells were stimulated with FGF2, and FGFR2 was immunoprecipitated with anti-FGFR2 polyclonal
antibody. Immunoprecipitates were then subjected to SDS-PAGE and immunoblot analysis using the anti-phospho-S779 phospho-specific
antibodies.
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results suggest a possible role for the PKC family of kinases in
regulating S779 phosphorylation.
FGFR2 regulates specific intracellular signaling pathways
via S779. The regulation of S779 phosphorylation and 14-3-3
recruitment in response to FGF2 stimulation raised the possi-
bility that these events may be important in mediating FGFR2
intracellular signaling. We therefore examined the possible
role of S779 in regulating two major FGF signaling pathways:
namely the Ras/MAP kinase pathway (by examining ERK
phosphorylation) and the PI 3-kinase pathway (by examining
Akt phosphorylation). As shown in Fig. 4A, B, and C, there
was no apparent difference in the ability of FGF2 to promote
Akt and ERK phosphorylation in Ba/F3 cells expressing either
the wt FGFR2 or the FGFR2-Y766F mutant. However, we
observed that Akt phosphorylation was significantly reduced by
more than 60% in cells expressing both the FGFR2-S779G
mutant (Fig. 4A and B) and the FGFR2-Y766F/S779G mutant
(Fig. 4A and B) compared to cells expressing wt FGFR2.
FIG. 3. The regulation of S779 and receptor tyrosine phosphorylation by wt and mutant FGFR2s. (A and C) Ba/F3 cells expressing either wt
FGFR2, FGFR2-Y766F, FGFR2-S779G, or FGFR2-Y766F/S779G were starved in medium containing 0.1% FCS for 4 h and then stimulated with
20 ng/ml FGF2 for the indicated times. Cells were lysed, FGFR2 was immunoprecipitated, and the immunoprecipitates were subjected to
SDS-PAGE and immunoblot analysis with either the 4G10 antiphosphotyrosine monoclonal antibody (P-Y), anti-phospho-S779, or anti-FGFR2
polyclonal antibody. (B) BALB/c 3T3 cells expressing either wt FGFR2, FGFR2-Y766F, FGFR2-S779G, or FGFR2-Y766F/S779G were starved
for 24 h and then stimulated with FGF2 as above. FGFR2 immunoprecipitates were then subjected to immunoblot analysis as in panel A. (D) wt
FGFR2 cells were starved as described for panel A with the inclusion of indicated inhibitors 30 min prior to stimulation with FGF or followed by
stimulation with PMA. FGFR2 immunoprecipitates were then subjected to immunoblot analysis as in panel A. Results shown are representative
of at least two experiments.
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Similarly, compared to cells expressing wt FGFR2, ERK phos-
phorylation was reduced by 58% in cells expressing the
FGFR2-S779G mutant and by 77% in cells expressing the
FGFR2-Y766F/S779G mutant (Fig. 4A and C).
To further investigate the role of S779 in PI 3-kinase signal-
ing, we examined the ability of FGF2 to induce the membrane
localization of a fusion protein containing the PH domain of
Akt1 and green fluorescent protein ([GFP] PH-Akt1-GFP).
The PH-Akt1-GFP binds PI (3, 4, 5) triphosphate (PIP3) in the
plasma membrane following PI 3-kinase activation, and this
localization can be observed by confocal fluorescence micros-
copy (16). Ba/F3 cells expressing either wt or mutant FGFR2
were transfected with a construct for the expression of PH-
Akt1-GFP, starved of factor, and then stimulated with either
FIG. 4. S779 of FGFR2 is required for signaling via the PI 3-kinase and Ras/MAP kinase pathways. Ba/F3 cells expressing either wt FGFR2,
FGFR2-Y766F, FGFR2-S779G, or FGFR2-Y766F/S779G were starved and stimulated with FGF2 as described in the legend to Fig. 2. Cell lysates
were then subjected to SDS-PAGE and immunoblotted with anti-phospho-Akt, anti-phospho-ERK, and anti-ERK1/2 polyclonal antibody or
antiactin polyclonal antibody (A). Quantitation of the phospho-Akt (B) or phospho-ERK1/2 (C) signals from two independent experiments is
shown (*, P  0.02; **, P  0.008). Ba/F3 cells expressing either wt FGFR2, FGFR2-Y766F, FGFR2-S779G, or FGFR2-Y766F/S779G were
electroporated with a construct for the expression of a fusion protein containing GFP and the PH domain of Akt1 (PH-Akt1-GFP). After 24 h,
cells were starved and stimulated with FGF2 or IL-3 (positive control) for the indicated times as described in the legend to Fig. 2. Cells were fixed,
and the localization of PH-Akt1-GFP was analyzed by confocal fluorescence microscopy (D). Arrows indicate membrane localization of PH-
Akt1-GFP. (E) The regulation of GSK3 and PLC- phosphorylation in response to FGF2 was determined as described for panel A. Quantitation
of phospho-GSK3 signals from two independent experiments is shown. Results are representative of at least two experiments.
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IL-3 (control) or FGF2. As shown in Fig. 4D, FGF2 stimula-
tion of cells expressing wt FGFR2 or FGFR2-Y766F resulted
in the translocation of PH-Akt1-GFP to the plasma membrane
at 5 min (Fig. 4D, arrows) and subsequent redistribution to the
cytoplasm at 15 min (Fig. 4D), indicating that PIP3 production
in response to FGF2 was both rapid and transient. However,
no such localization was observed for either the FGFR2-
S779G or the FGFR2-Y766F/S779G mutants following FGF2
stimulation at either 5 or 15 min, indicating a defect in the
activation of PI 3-kinase and the generation of PIP3.
While the results shown in Fig. 4A, B, and D indicated that
the FGFR2-S779G mutant was defective in PI 3-kinase signal-
ing in response to FGF2, we did not observe any significant
defect in the phosphorylation of the downstream PI 3-kinase
target, GSK3 (Fig. 4E and F). These results would suggest that
GSK3 phosphorylation in response to FGF2 may occur via a PI
3-kinase- and Akt-independent pathway in Ba/F3 cells. In fact,
others have shown that GSK3 can be phosphorylated by PKA
and PKC independently of PI 3-kinase activity (11, 67). Alter-
natively, it is also possible that the residual Akt phosphoryla-
tion observed for the S779G mutant in Fig. 4A was sufficient
for phosphorylation of GSK3. In addition, no difference in
Y783 phosphorylation of PLC- following FGF2 stimulation
was observed between cells expressing the wt and mutant
FGFR2s (Fig. 4E).
FRS2 has been shown to play an important role in the ability
of the FGFRs to promote both PI 3-kinase signaling and Ras-
MAP kinase signaling (20, 23). However, we were unable to
detect FRS2 phosphorylation in response to FGF2 in Ba/F3
cells expressing either wt or mutant receptors (data not
shown). Despite the lack of detectable FRS2 phosphorylation,
wt FGFR2 was clearly able to promote PI 3-kinase and Ras-
MAP kinase signaling (Fig. 4) as well as proliferation and
survival of Ba/F3 cells (see below). In this respect, it is note-
worthy that others have observed FGFR2 intracellular signal-
ing and biological responses in the absence of detectable FRS2
tyrosine phosphorylation (21, 27).
We then sought to determine whether the observed defects
in receptor signaling for the FGFR2-S779G mutant were due
to defects in receptor dimerization, stability, or internalization.
To examine receptor dimerization, we utilized the BS3 cross-
linker that allows the amine-reactive N-hydroxysulfosuccinim-
ide ester at each end of an 8-carbon spacer arm to form stable
bonds, with primary amines such as side chains of lysine resi-
dues (61). FGF2 stimulation of cells expressing the wt FGFR2
in the presence of the BS3 chemical cross-linker resulted in a
mobility shift consistent with the formation of ligand-induced
higher-order oligomeric FGFR2 complexes (Fig. 5A, asterisk).
Importantly, no significant difference in the formation of BS3-
cross-linked receptor oligomers was observed between the wt
and the FGFR2-S779G receptors (Fig. 5A). These results in-
dicate that the S779G mutant was not defective in ligand-
induced dimerization and are consistent with the data shown in
Fig. 3 demonstrating that the S779G mutant was not defective
in mediating ligand-induced receptor tyrosine phosphoryla-
tion.
We then compared the half-life of the FGFR2-S779G mu-
tant to the wt receptor by examining the loss of FGFR2 in the
presence of protein synthesis inhibitor, cycloheximide. As
shown in Fig. 5B, protein stability of the wt FGFR2 and the
FGFR2-S779G mutant was similar both in the absence of
FGF2 (steady-state half-life, 9.3  2.2 and 9.6  0.5 h, respec-
tively) and following FGF2 stimulation (ligand-induced half-
life, 8.9  1.7 and 8.1  0.2 h, respectively).
Finally, we examined whether receptor internalization fol-
lowing FGF2 stimulation was defective for the S779G mutant.
Using confocal fluorescence microscopy to localize FGFR2
together with a phalloidin counterstain to decorate cortical
actin at the plasma membrane, we show that both the wt and
the FGFR2-S779G mutant are internalized following FGF2
stimulation (Fig. 5C). Collectively, the results shown in Fig. 5
indicate that the observed defects in receptor signaling for the
FGFR2-S779G mutant were not simply due to defects in either
receptor dimerization, stability, or internalization.
FGFR2 regulates cell proliferation and survival via S779.
To determine the functional consequences of S779 phosphor-
ylation and 14-3-3 signaling, we first examined the ability of
FGF2 to promote the growth and viability of Ba/F3 cells ex-
pressing wt and mutant FGFR2s using the colorimetric MTS
reduction assay. While FGF2 promoted a dose-dependent in-
crease in MTS signal in cells expressing the wt and the FGFR2-
Y766F mutant, this response was markedly reduced in the
FGFR2-S779G and FGFR2-Y766F/S779G mutants (Fig. 6A).
We further examined whether this functional defect in the
FGFR2-S779G mutant also occurred in BALB/c 3T3 cells sta-
bly transfected with wt and mutant FGFR2s in the MTS assay.
While FCS provided a potent mitogenic signal in all BALB/c
3T3 cell lines (positive control), cells expressing the FGFR2-
S779G and the FGFR2-Y766F/S779G mutants demonstrated
significantly reduced responses to FGF2 compared to cells
expressing wt FGFR2 (Fig. 6B).
We then examined whether the defect observed in the MTS
assay for the FGFR2-S779G mutant was specifically due to
inability of FGF2 to promote cell survival. First, we examined
cell death by quantifying the reduction in the number of viable
cells containing 2N DNA (i.e., the sub-G0/G1 population)
using propidium iodide staining and flow cytometry analysis.
FGF2 was able to promote increased viability (as determined
by 2N DNA content) in cells expressing wt FGFR2 and the
FGFR2-Y766F mutant; however, no such response was ob-
served in cells expressing the FGFR2-S779G or the FGFR2-
Y766F/S779G mutants (Fig. 7A). To further determine
whether the mode of cell death involved apoptosis, we specif-
ically examined the loss of mitochondrial membrane potential
using the fluorometric dye TMRE (15, 65). In the absence of
FGF2, no TMRE retention was observed in cells expressing
the wt FGFR2, indicating a loss of mitochondrial membrane
potential associated with apoptosis. Although FGF2 was able
to promote TMRE retention in cells expressing the wt FGFR2
and the FGFR2-Y766F (Fig. 7B), TMRE retention was signif-
icantly reduced in cells expressing either the FGFR2-S779G or
the FGFR2-Y766F/S779G mutants (Fig. 7B), indicating that
S779 of FGFR2 was critical in specifically regulating cell sur-
vival in response to FGF2.
We also examined the ability of the wt and mutant FGFR2s
to promote cell proliferation by examining S phase entry using
BrdU incorporation in response to FGF2. While FGF2 was
able to promote the S phase entry of Ba/F3 cells expressing
either the wt FGFR2 or the FGFR2-Y766F, S phase entry of
the FGFR2-S779G and the FGFR2-Y766F/S779G mutants
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was significantly reduced (Fig. 8A). We further examined this
defect in cell proliferation by analyzing the cell cycle distribu-
tion using propidium iodide staining of fixed cells followed by
flow cytometry analysis. Cells expressing the wt FGFR2 and
the FGFR2-Y766F mutant and growing asynchronously in
FGF2 demonstrated similar cell cycle distributions. However, a
significant reduction in the ability of FGF2 to promote entry
into S phase in cells expressing the FGFR2-S779G and the
FGFR2-Y766F/S779G mutants was observed (Fig. 8B). To-
gether, our data demonstrate an important functional role for
FIG. 5. Receptor dimerization, stability, and internalization are not affected in the FGFR2-S779G mutant. (A) Ba/F3 cells expressing either wt
FGFR2 or FGFR2-S779G were incubated in the presence of FGF for 4 h and then left untreated or treated with BS3 cross-linker, lysed, and
subjected to SDS-PAGE and immunoblotting with anti-FGFR2 polyclonal antibody. (B) Ba/F3 cells expressing either wt FGFR2 or FGFR2-S779G
were plated in medium containing 10% fetal calf serum, 10% WEHI, and 10 g/ml cycloheximide in the presence or absence of 20 ng/ml FGF2
for up to 24 h. Cells were then lysed and subjected to SDS-PAGE and immunoblotted with anti-FGFR2 polyclonal antibody. (C) Ba/F3 cells
expressing either wt FGFR2 or FGFR2-S779G were starved in medium containing 0.1% FCS for 4 h prior to stimulation with 20 ng/ml FGF for
0, 15, and 60 min. Cells were fixed and stained with anti-FGFR2 polyclonal antibody (green) and costained with phalloidin (red). Results are
representative of at least two experiments.
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S779 of FGFR2 and 14-3-3 signaling in regulating FGF2-me-
diated intracellular signaling and cellular responses.
DISCUSSION
The ability of phosphotyrosine docking sites in the cytoplas-
mic tails of growth factor receptors to bind SH2 and PTB
domain proteins represents an important paradigm by which
intracellular signaling and cellular responses are controlled.
We now show that in addition to phosphotyrosine residues, a
specific phosphoserine residue in the cytoplasmic domain of
FGFR2 functions as a docking site for the 14-3-3 family of
phosphoserine-binding proteins to regulate intracellular sig-
naling pathways and biological responses. We have identified a
conserved serine in the C-terminal lobe of FGFR2 (S779) that
is phosphorylated in response to FGF2 stimulation and binds
the 14-3-3 proteins (Fig. 2). Using the Ba/F3 model system to
examine FGF2-mediated signaling and cellular responses (22,
26, 42, 59, 66), we have shown that a FGFR2-S779G mutant
was not only unable to bind the 14-3-3 proteins but also dem-
onstrated reduced Akt and ERK phosphorylation in response
to ligand (Fig. 2 and 4). These results were in contrast to the
FGFR2-Y766F mutant (that has been previously shown to be
defective in PLC- signaling), which showed no defect in Akt
or ERK phosphorylation (Fig. 4). Significantly, the FGFR2-
S779G mutant that showed defective PI 3-kinase and Ras/
MAP kinase signaling was also unable to support the survival
or proliferation of Ba/F3 cells in response to FGF2 (Fig. 6, 7,
and 8). No difference in FGFR2 tyrosine phosphorylation was
observed between the wt and any of the mutant receptors,
indicating that the inability of the FGFR2-S779G mutant to
promote cell viability and proliferation was not simply due to
an overall defect in receptor activation (Fig. 3). Furthermore,
the inability of the FGFR2-S779G mutant to promote cell
survival and proliferation was also simply not due to a global
defect in the activation of all downstream signaling pathways.
The defect in the ability of the FGFR2-S779G mutant to reg-
ulate cell survival and proliferation compared to the wt FGFR2
was not due to either (i) reduced ligand-induced receptor
dimerization, (ii) altered protein stability, or (iii) reduced re-
ceptor internalization (Fig. 5). Rather, our results show that
only specific FGFR2 signaling outputs appeared to be affected
by the S779G mutation. This was evident from the ability of the
FGFR2-S779G mutant to normally regulate GSK3 and PLC-
FIG. 6. S779 of FGFR2 promotes cell viability in response to
FGF2. (A) Ba/F3 cells expressing either wt FGFR2, FGFR2-Y766F,
FGFR2-S779G, or FGFR2-Y766F/S779G were plated in medium con-
taining 0.1% FCS and the indicated concentrations of FGF2. IL-3 was
used as a positive control. After 24 h, the colorimetric MTS reduction
assay was performed according to the manufacturer’s instructions, and
absorbance was measured at 490 nm. (B) In addition, the response of
BALB/c 3T3 cells expressing either wt FGFR2, FGFR2-Y766F,
FGFR2-S779G, or FGFR2-Y766F/S779G was also examined using the
MTS assay. Cells were plated in medium containing 10% BIT in the
presence or absence of FGF2. FCS (10%) was used as a positive
control. Cellular responses were measured after 3 days using the MTS
assay. All results shown are representative of at least two experiments.
Error bars represent standard deviations. *, P  6  10
5.
FIG. 7. S779 of FGFR2 regulates cell survival in response to FGF2.
(A) Ba/F3 cells expressing either wt FGFR2, FGFR2-Y766F, FGFR2-
S779G, or FGFR2-Y766F/S779G were plated in medium containing 0.1%
FCS in the presence or absence of 20 ng/ml FGF2. After 24 h, the cells
were fixed, stained with propidium iodide, and analyzed by flow cytom-
etry. The percentage of viable cells (2N DNA) is shown. (B) Cells were
plated as above in the indicated concentrations of FGF2 and after 24 h
were stained with TMRE and analyzed by flow cytometry. Shown is the
percentage of cells demonstrating TMRE retention indicating intact mi-
tochondrial potential. All results shown are representative of at least three
experiments. Error bars represent standard deviations (*, P  0.05).
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phosphorylation while other signaling events such as the phos-
phorylation of Akt and ERK were clearly disrupted (Fig. 4).
Together, these results identify a new FGF signaling pathway
in which phosphorylation of S779 in the cytoplasmic domain of
FGFR2 provides a docking site for the 14-3-3 proteins and
couples the activated receptor to specific signaling pathways
biological responses.
In terms of the kinase that phosphorylates S779, it is known
that the recognition motifs for some AGC-family serine/threo-
nine kinases include basic residues N-terminal to the phospho-
serine and therefore partially overlap with the prototypic mode
1 and mode 2 14-3-3 consensus binding motifs (R-S-X-S/T-X-P
and R-X-	-X-S/T-X-P [for underlining, see Results]) (71).
Thus, a number of AGC kinases, including Akt and PKA, have
been shown to phosphorylate 14-3-3 binding sites in diverse
proteins (1, 30). In the case of the GM-CSF and IL-3 receptors,
we have shown a role for PKA in phosphorylating S585 of the
c subunit (19). However, the QYSPSYP motif in FGFR2
does not strictly conform to classic mode 1 or mode 2 recog-
nition sequences and does not constitute a consensus PKA
phosphorylation site (47). Nevertheless, the S779 motif in
FGFR2 resembles the 14-3-3 binding sites identified in other
proteins such as the mouse c subunit of the GM-CSF receptor
(600QSHSLP605) (our unpublished data), p53 (380QSTpSRH385),
and AMP-activated kinase family QSK (159QLIKTWC165)
(2, 68). Thus, in order to identify candidate kinases involved in
S779 phosphorylation, we performed Predikin analysis (3).
This analysis revealed PKC, IKK, Akt, and GSK3 as potential
hits. We then examined the pharmacological profile of these
kinases in terms of S779 phosphorylation. We showed that
inhibition of IKK, Akt, and GSK3 did not reduce S779 phos-
phorylation (Fig. 3D). However, we also showed that pharma-
cological activation of PKC with PMA resulted in the ligand-
independent phosphorylation of S779. Thus, our results
suggest a role for the PKC family of kinases in phosphorylating
S779. Others have shown important roles for PKC in FGF-
mediated biological responses. For example, a role for PKC-ε
in the FGF2-mediated survival of small cell lung cancer cells
has been suggested (43). In addition, while EGF stimulation of
the PC12 pheochromocytoma cells line normally promotes
proliferation, costimulation of these cells with EGF and PMA
converts the EGF-proliferative response into an FGF-like dif-
ferentiation response, and the cells develop neurite-like out-
growths (53). Furthermore, small interfering RNA of PKC-
reduced FGF-mediated PC12 differentiation, suggesting an
important role for PKC- in mediating at least some specific
biological responses (53). While it is not clear which of the
more than 10 members of the PKC family of kinases is impor-
tant for S779 phosphorylation, our results show an important
role for S779 signaling in regulating specific FGF biological
responses.
In the same manner as phosphotyrosine residues are able to
promote the reversible assembly of signaling complexes via the
binding of SH2 and PTB domain proteins, phosphoserine/
threonine residues have been shown to act as docking sites for
the 14-3-3 proteins (4, 33, 39, 40, 52, 57). However, while the
binding of SH2 and PTB domain proteins to phosphotyrosine
residues in the cytoplasmic domains of growth factor and cy-
tokine receptors has been widely demonstrated to allow the
dynamic regulation of intracellular signaling pathways, it is
only very recently that the phosphorylation of receptor serine
residues and the binding of the 14-3-3 proteins have been
reported. For example, our earlier studies have shown that
S585 in the cytoplasmic domain of the c subunit in the GM-
CSF and IL-3 receptors is phosphorylated in response to ligand
and binds the 14-3-3 proteins (19, 62). Importantly, these ear-
lier studies showed that S585 phosphorylation and 14-3-3 bind-
ing were required for the regulation of PI 3-kinase signaling
and cell survival (19). Subsequent studies have shown that S585
phosphorylation of c couples to distinct signaling pathways
and biological responses compared to c tyrosine phosphory-
lation, providing a mechanistic explanation for how GM-CSF
and IL-3 are able to regulate pleiotropic (or diverse) biological
responses (17, 18). Thus, our studies examining growth factor
and cytokine receptors now establish a new mode of signaling
involving receptor serine phosphorylation and 14-3-3 signaling
that performs essential roles in mediating specific cellular re-
sponses.
Other examples have been reported in which receptor serine
phosphorylation and 14-3-3 binding have been shown to regu-
late intracellular signaling pathways. For example, a 14-3-3
binding site in the C-terminal lobe of the IGF-1R has been
identified (4). Subsequent studies have examined the possible
functional roles of specific tyrosine and serine residues in the
cytoplasmic domain of IGF-1R by examining the ability of wt
FIG. 8. S779 of FGFR2 regulates cell proliferation in response to
FGF2. (A) Ba/F3 cells expressing either wt FGFR2, FGFR2-Y766F,
FGFR2-S779G, or FGFR2-Y766F/S779G were plated in medium con-
taining 0.1% FCS in either 0, 0.5, or 5 ng/ml FGF2. After 24 h, cells
were pulsed with BrdU for 3 h, fixed, and stained with anti-BrdU-FITC
monoclonal antibody, following which the cells were analyzed for
BrdU incorporation by flow cytometry. (B) Cells were plated as above
and after 24 h were fixed and stained with propidium iodide. Cell cycle
distribution was then determined by flow cytometry. The percentage of
cells in S phase was quantified from three experiments, and the results
are shown. Error bars represent standard deviations (*, P  0.05).
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and mutant receptors to promote intracellular signaling as well
as cell proliferation and survival in the murine 32D factor-
dependent cell line (48). These studies showed that mutating
key serine residues within the 14-3-3 binding site of IGF-1R
reduced the ability of IGF-1 to promote mitochondrial trans-
location of Raf1, the phosphorylation of BAD, and the survival
of 32D cells (48). Thus, the dual ability of receptor serine
phosphorylation and 14-3-3 signaling together with receptor
tyrosine phosphorylation and SH2 and PTB domain protein
signaling may be essential for promoting diversity in signaling
and specificity in cellular responses.
The identification of a specific serine phosphorylation site
in FGFR2 that regulates a 14-3-3 signaling pathway leading
to cell proliferation and survival has important implications
in terms of how the FGFs are able to regulate pleiotropic
biological responses. Since the discovery of the prototypic
family members, FGF1 and FGF2, a large number of studies
have shown that the FGFs coordinately regulate diverse
cellular responses including cell survival, proliferation, and
differentiation that underpin key processes involved in de-
velopment, hematopoiesis, angiogenesis, and tissue repair
(7, 9, 50, 64). In fact, the use of gene knockout approaches
in mice has demonstrated that FGFs and their cognate re-
ceptors are able to dictate multiple and diverse cell fates,
providing an extensive picture of their pleiotropic functions
(9). However, the underlying mechanisms by which the
FGFRs regulate these diverse functions remain largely un-
defined. While a number of reports have examined the link
between individual FGFR tyrosine residues and specific
FGF-mediated biological responses (5, 6, 12, 22, 25, 35, 38,
44, 51), it is still not known how the FGFs are able to specify
different cellular outcomes. While there is clear evidence
that specific tyrosine residues in some RTKs provide qual-
itatively unique signals that mediate defined cellular re-
sponses (46), some studies have reported redundancy in
receptor tyrosine phosphorylation and have suggested that
RTKs may generate generic tyrosine signals that are inter-
preted in quantitatively different manners to promote spe-
cific cellular outcomes (10, 31, 56, 63). Our studies now
provide a new and alternative mechanism by which growth
factor receptors promote the activation of specific intracel-
lular signaling pathways and biological responses and sug-
gest that receptor serine phosphorylation, in addition to
receptor tyrosine phosphorylation, may play essential roles
in regulating pleiotropic biological responses.
It is noteworthy that the motif encompassing the PLC- and
14-3-3 binding sites in FGFR2 demonstrate high sequence
homology to the GM-CSF receptor motif encompassing the
Shc and 14-3-3 binding sites we described in our earlier studies
(17, 18). We therefore performed database searches to identify
similar putative phosphotyrosine/phosphoserine “bidentate
motifs” in other cell surface receptors. As shown in Table 1,
these searches have identified a number of receptors that con-
tain similar conserved phosphotyrosine/phosphoserine biden-
tate motifs. It is noteworthy that the 14-3-3 binding site at S779
in FGFR1 and FGFR2 is not conserved in FGFR3 and
FGFR4. In this regard, it is interesting that FGFR4 is unable
to regulate cell proliferation of Ba/F3 cells (66), and FGFR3 is
significantly less potent than FGFR1 in promoting PC12 cell
differentiation (26). Each motif in Table 1 consists of a con-
served putative PTB or SH2 binding site that is followed by a
conserved putative 14-3-3 binding site and is found in diverse
growth factor, cytokine, and integrin receptors. Thus, our re-
sults suggest that such bidentate motifs intersect the activation
of distinct molecular pathways downstream of functionally
TABLE 1. Identification of putative conserved phosphotyrosine/serine motifs in diverse cell surface receptors
Name
Conserved motif
Accession no.Start
positiona Sequence
b
FGFR2 (Bek) 763 NEEYLLSQPLE......................QYSPSYP P21802
GM-CSF/IL-3/IL-5 receptor c subunitc 590 NGPYLGPP..........................HSRSLP NP_000386
FGFR1(Flg) 763 NQEYLDLSIPLD.....................QYSPSFP P11362
ErbB4 1239 NPDY..............................WNHSLP NP_005226
Low-density lipoprotein receptor-related protein 1 4470 NPTYKMYEGGEPDDVGGLLDADFALDPD....KPTNFTNP Q07954
Low-density lipoprotein receptor 802 NPVYQKTTEDEVHICHN................QDGYSYP AAF24515
Very-low-density lipoprotein receptor 834 NPVYLKTTEEDLSIDIG................RHSASVG NP_003374
Integrin beta 1 (fibronectin receptor) 780 NPIY............................KSAVTTVV NP_002202
Integrin beta 3 (platelet glycoprotein IIIa) 770 NPLYKEA..........................TSTFTNI NP_000203
Integrin beta-6 759 NPLYR............................GSTSTFK A37057
Integrin beta-7 775 NPLYKS...........................AITTTIN P26010
ErbB3 972 PPRYLVI...........................KRESGP P21860
FLT3 receptor tyrosine kinase 916 EEIYIIMQSCWAFDS..................RKRPSFP CAA81393
Vascular endothelial growth factor receptor 2 1220 ISQYLQNS..........................KRKSRP AAC16450
Granulocyte colony stimulating factor receptor 764 PGHYL.............................RDSTQP Q99062
IL-6 receptor beta chain (glycoprotein 130) 764 HSGYRHQVPSVQVFS..................RSESTQP P40189
TrkB tyrosine kinase (BDNF/NT-3 receptor) 752 QPWYQLSNNEVIECITQGRVL............QRPRTCP Q16620
Platelet-derived growth factor receptor alpha 608 GTAY.............................GLSRSQP P16234
c-Met 1023 QVQYPLTDMSPILTSG.................DSDISSP P08581
Macrophage-stimulating protein receptor (p185-Ron) 1357 PATYMNLGPSTSHEMNVRPEQPQFSPMPGNVRRPRPLSEP Q04912
IGF-1R 1278 SFYYSEENKLPEPEELDLEPENMESVPLD..PSASSSSLP NP_000866
a Residue number.
b The tyrosine and serine residues in boldface in each motif are conserved between at least three species including, human, mouse, and rat.
c References 15 and 16.
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diverse signaling proteins to regulate pleiotropic cellular
responses.
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